Work

Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing

Year: 2018

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2018-99-113419

Authors: Evgeny Arons, Daniel Gorelik, Maryalice Stetler-Stevenson, Constance M. Yuan, Mark Sokolsky, Hong Zhou, Nai Shun (nancy) Yao, Shannon Marshall, Katherine Potocka, Erin Fykes, Ira Pastan, Robert J. Kreitman

Institutions: National Institutes of Health, National Cancer Institute

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2902900111

Cites:

Cited by: 1

Related to: 10